Composite phaeochromocytomas - a systematic review of published literature by Dhanasekar, K. et al.
This is a repository copy of Composite phaeochromocytomas - a systematic review of 
published literature.




Dhanasekar, K., Visakan, V., Tahir, F. et al. (1 more author) (2021) Composite 
phaeochromocytomas - a systematic review of published literature. Langenbeck's Archives





This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
REVIEW ARTICLE
Composite phaeochromocytomas—a systematic review
of published literature
K. Dhanasekar1 & V. Visakan2 & F. Tahir3 & S. P. Balasubramanian1,3
Received: 2 December 2020 /Accepted: 9 February 2021
# The Author(s) 2021
Abstract
Introduction Composite phaeochromocytoma is a tumour containing a separate tumour of neuronal origin in addition to a
chromaffin cell tumour. This study reports on two cases from a single centre’s records and presents a systematic literature review
of composite phaeochromocytomas.
Methods In addition to describing 2 case reports, a systematic search of the Medline database from inception up to April 2020 was
done for human case reports on composite phaeochromocytomas. Relevant titles and/or abstracts were screened, and full texts were
reviewed to identify appropriate studies. Data was extracted and a descriptive analysis of presentation, clinical features, management
strategies and outcomes was performed. The quality of included studies was assessed using a critical appraisal checklist.
Results There were 62 studies included, with a total of 94 patients. Of 91 patients where data was available, the median (range)
age of patients was 48 (4–86) years. Of 90 patients where information was provided, 57%were female. In at least 28% of patients,
a genetic cause was identified. Common presenting features include abdominal pain, palpable mass, cardiovascular and gastro-
intestinal symptoms. The most common tumour component with phaeochromocytoma is ganglioneuroma; other components
include ganglioneuroblastoma, neuroblastoma and malignant peripheral nerve sheath tumours. In patients with follow-up data
(n=48), 85% of patients were alive and well at a median (range) follow-up time of 18 (0.5–168) months.
Conclusion Composite phaeochromocytoma is a rare tumour, with a significant genetic predisposition. This review summarises
available epidemiological data, which will be useful for clinicians managing this rare condition.
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Introduction
Phaeochromocytomas are chromaffin cell tumours
characterised by the excessive production and secretion of
catecholamines. These tumours usually arise in the adrenal
medulla but occasionally from chromaffin cells of the sympa-
thetic ganglia; here they are called paragangliomas. These
tumours occur in approximately 0.5–2 patients per 1000 with
hypertension [1]. Diagnosis is typically made between the
third and fifth decades; up to 30% of phaeochromocytomas
have a genetic predisposition including syndromes such as
von Hippel-Lindau syndrome, neurofibromatosis type 1
(NF-1) and multiple endocrine neoplasia (MEN) syndrome
type II [2, 3].
Approximately 15% of phaeochromocytomas are malig-
nant [4]. Patients may present with sustained or paroxysmal
hypertension, with associated symptoms such as headaches,
sweating, palpitations and tremor [4], caused by the excessive
release of catecholamines. Initial biochemical investigations
include plasma and/or urine catecholamine and metanephrine
levels. If these are elevated, imaging to locate a potential tu-
mour includes CT and/or MRI scans. If these scans are incon-
clusive, nuclear medicine imaging using radiotracers 123I-
metaiodobenzylguanidine (MIBG scan) [1] and more recently
gallium-68 dotatate PET (68GA-PET) scans may also be use-
ful [5, 6].
Surgery (usually by laparoscopy) after preoperative alpha
blockade is the recommended intervention. Alpha blocker
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therapy is traditionally used reduce the risk of perioperative
cardiovascular complications [1, 7]. The prognosis after sur-
gery is very good for benign tumours; the 5-year survival rate
is 95%; however, this drops to 50% in malignant tumours [1].
Treatment of metastatic disease is not well understood due to
tumour rarity. Chemotherapy, radionuclide agents such as
iobenguane 131I, tyrosine kinase inhibitors such as sunitinib
and immunotherapeutic agents such as pembrolizumab have
Fig. 1 Low power view (×4)
showing pheochromocytoma
(solid black arrow) and
ganglioneuroma (solid white
arrow) as part of the composite
phaeochromocytoma. The inset
shows chromogranin A staining
at ×10 magnification
Fig. 2 Low power view (×4) with
background adrenal (solid black
arrow) in the left upper part of the
picture and composite
pheochromocytoma on the right.
The inset is a high-power view
(×10) showing pheochromocyto-
ma on the left (solid black arrow)
and ganglioneuroma on the right
(solid white arrow)
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been reported; however, clinical trials for these treatments are
ongoing [8]. Long-term follow-up is important in both benign
and malignant pathology to ensure that recurrences are detect-
ed promptly [1].
Ganglioneuromas are rare tumours of autonomic ganglion
cells of the nervous system. They are usually benign and often
arise in the posterior mediastinum and retroperitoneum. They
rarely occur in the adrenal gland, accounting for 0.3–2% of all
adrenal incidentalomas [9]. Most adrenal ganglioneuromas
are discovered incidentally on CT scans as they are largely
asymptomatic and hormonally inactive. However, 30% of pa-
tients with ganglioneuromas are found to have raised plasma
and urinary metanephrines [10]. Diagnosis can only be con-
firmed on histology after resection and prognosis is extremely
good [9, 10].
Rarely, phaeochromocytomas may be part of a composite
tumour [11], where there is another type of tumour (usually of
the same embryological origin, i.e. neural crest) present.
Tumour types that co-exist with phaeochromocytomas are
reported to include ganglioneuromas, schwannomas and
ganglioneuroblastomas [12, 13]. There are only a few docu-
mented cases in the literature, leading to uncertainty in the
understanding of the pathogenesis and natural history of these
conditions.
Fig. 3 Low power view (4x)
showing S100 staining highlight-
ing the Schwann cells and the
sustentacular cells of the com-
posite pheochromocytoma (solid
black arrows) but sparing the
ganglion cells (solid white arrow)
of the ganglioneuroma
Table 1 Summary of two cases
from host institution Case 1 Case 2
Gender Male Male
Age at presentation (years) 69 75
Composite tumour component Ganglioneuroma Ganglioneuroma
Underlying genetic syndrome NF-1 None
Presentation details Haematuria Incidental finding
Imaging modality CT, MIBG CT, FDG-PET
Primary management Laparascopic adrenalectomy Laparascopic adrenalectomy
Tumour diameter (cm) 4.5 6
Tumour laterality Left Left
Tumour PASS score 5/20 4/20
Outcome Alive without disease Alive without disease
Follow-up (months) 19 25
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The aim of this study was to report cases of composite
phaeochromocytomas seen in one centre and to undertake a
systematic review of the published literature to increase the
understanding of the epidemiology and clinical outcomes of
these rare tumours.
Methods
The histology reports of all patients who underwent resection
of phaeochromocytoma over a 19-year period were reviewed
to identify patients with composite tumours (defined as a tu-
mour including phaeochromocytoma as at least one of several
components). Two patients were identified in a review of 115
reports.
A systematic review of literature was performed to identify
all reports of patients with composite tumours including
phaeochromocytoma. The online database Medline was
searched (on April 16, 2020), via search engine PubMed using
the following combination of keywords:
& Phaeochromocytoma
& Composite OR combined OR incidental OR complex OR
co-existing OR coincidental OR associated
& Paraganglioma OR ganglioneuroma OR neurofibroma
OR schwannoma OR ganglioneuroblastoma OR
neurilemmoma OR neuroendocrine carcinoma
The titles and/or abstracts of all articles retrieved by the
search were reviewed independently by two authors to include
original human studies on patients with composite tumours
with phaeochromocytoma as one component. Studies on
non-composite tumours, animal studies and those not written
in the English language were excluded.
Full texts of articles considered suitable for inclusion were
reviewed against the same criteria. The bibliography of in-
cluded papers was also screened. Data from all included stud-
ies on demographics, clinic-pathological features and out-
comes were collected in an excel spreadsheet and analysed.
Included studies were also critically appraised using the
Joanne Briggs Institute (JBI) critical appraisal checklist for
case reports [14]. One point was awarded for each question
Table 2 Summary of
demographic, clinical
presentation, histology and
underlying genetic syndrome in
patients with composite
phaeochromocytoma
Category (n=number of patients
where data is available)
Classification Number of patients
Gender (n=90) Male 39 (42%)
Female 51 (54%)
Age (n=91) Median (range): 48 (4–86)





Underlying genetic syndrome (n=94) None 68 (73%)
NF-1 18 (19%)
MEN 2A 4 (4%)
von Hippel-Lindau syndrome 2 (2%)
WDHA syndrome2 2 (2%)
Presentation details (n=74) Incidental finding 35 (47%)
Abdominal pain/palpable mass 24 (32%)
Hypertension 18 (24%)
Headaches 14 (19%)
Weight loss 14 (19%)
Diarrhoea 12 (16%)
Palpitations and/or tachycardia 10 (14%)




*Other includes: “neuroendocrine carcinoma” (n=1), “ganglion cells in clusters” (n=1), “malignant peripheral
nerve sheath tumour” (MPNST—n=3), “MPNST sustentaculoma” (n=1), “MPNST-rhabdomyosarcoma—Triton
tumour” (n=1)
Langenbecks Arch Surg
if appropriate. Scores were reported as a percentage of the
total applicable questions.
Descriptive analyses included reporting of frequencies (or
percentages) for categorical data; median (range) for nonpara-
metric, continuous data and mean (SD) for parametric, con-
tinuous data.
As this was a systematic review of literature and presenta-
tion of case studies where all identifiable details have been
removed, no formal permission has been obtained from the





A 69-year-old gentleman with learning difficulty, hyperten-
sion and neurofibromatosis type I presented in 2019 with
haematuria. Abdominal examination only showed some neu-
rofibromas and a café au lait lesion. Investigations revealed no
definite cause, but CT scan of the urinary tract demonstrated
left (4.5 cm) and right (2 cm) adrenal nodules. Biochemical
testing demonstrated raised plasma and urine metanephrines,
confirming a diagnosis of phaeochromocytoma. I-123 MIBG
scans demonstrated uptake in both glands, but more on the left
side. Following discussions in a multi-disciplinary teammeet-
ing, the patient and his family, left adrenalectomy alone was
considered to avoid life-long steroid treatment. Regular sur-
veillance of metanephrine levels was considered preferable to
steroid treatment, as compliance with medications was an is-
sue. After preoperative alpha blockade and with perioperative
steroids, a left laparoscopic adrenalectomy was performed un-
eventful ly. He was discharged on a low dose of
phenoxybenzamine and bisoprolol. Histology showed fea-
tures of a composite phaeochromocytoma-ganglioneuroma
(Fig. 1) with a PASS score of 5/20. The patient and his
metanephrine levels 19 months after surgery were
satisfactory.
Case 2
A 75-year-old gentleman was incidentally found to have a
6-cm left adrenal lesion on CT scan for a new diagnosis
Table 3 Imaging modalities used, primary management and clinical outcomes of patients with composite phaeochromocytoma
Category (n=number of patients
where data is available)
Classification Number of patients
Imaging modality (n=57) CT 45 (78%)—solitary modality in 24 (42%)
MRI 15 (26%)
MIBG 21 (37%)—with CT in 11 (19%),
with MRI in 5 (9%)
Ultrasound 4 (7%)
Primary management (n=74) Adrenalectomy 66 (90)
None—autopsy after death 6 (8%)
Radiotherapy 1 (1%)
Chemotherapy (for neuroblastoma metastases) + adrenalectomy 1 (1%)
Tumour diameter (n=81) Median (range): 4.98cm (1.5–26)
Tumour laterality (n=59) Left (n=23, 39%) Laparoscopic 4 (7%)
Unspecified 19 (32%)
Right (n=33, 56%) Laparoscopic 5 (8%)
Unspecified 28 (48%)
Bilateral (n=3, 5%) Laparoscopic 3 (5%)
Unspecified 8 (14%)
Outcomes (n=70) Alive without disease 55 (79%)
Alive with metastases 1 (1%)
Death from composite tumour 10 (14%)
Death from other disease* 4 (6%)
Follow up time (n=48) Median (range): 18 months (2 weeks–14 years)
Time between primary management
and death (n=7)
Median (range): 8 months (3–168 months)
*Other causes of death include colorectal cancer (n=1), non-small cell lung cancer (n=1), bladder cancer (n=1) and myocardial infarction (n=2)
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of prostate cancer. He had hypertension and gout. A fur-
ther fluorodeoxyglucose (FDG) PET scan demonstrated
raised uptake and biochemistry confirmed raised
metanephrine levels, confirming the diagnosis of
phaeochromocytoma. After alpha blockade, the patient
underwent an uneventful laparoscopic left adrenalectomy.
Histology showed a composite tumour with two
c o m p o n e n t s — p h a e o c h r o m o c y t o m a a n d
ganglioneuroma—with a PASS score of 4/20 (Figs. 2
and 3). He was well at 25 months following surgery.
Data from these two cases are summarised in Table 1.
The process of inclusion and exclusion of articles for this
review is shown in a modified PRISMA flow diagram (Fig.
4). In total, 62 studies published between the years 1943 and
2017 involving 94 patients were included [15–73]. Of these
studies, 51 were single-case reports. Of the 90 patients where
gender information was available; there were 39 males (42%)
and 51 females (54%). The median (range) age of patients
where this information was available (n=91) was 48 (4–86)
years. Data on patient demographics, tumour size and histol-
ogy, underlying genetic syndrome and presentation details is
presented in Table 2. Data on genetic syndromes and on
Fig. 4 Modified PRISMA flow diagram showing the process of inclusion and exclusion of articles included in this review
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composite tumour components are displayed in Fig. 5 and Fig.
6, respectively. Data on imaging modalities used, primary
management, tumour laterality and removal method, patient
outcomes and follow-up times is displayed in Table 3.
Left-sided operations were performed in 23 instances with
4 specifically described as laparoscopic procedures; the re-
maining 19 were unspecified. Right-sided operations were
performed in 33 patients, with 5 specifically described as lap-
aroscopic procedures; the remaining 28 were unspecified. In 8
procedures, the laterality was not mentioned. Three of these
procedures were explicitly described as laparoscopic; the re-
maining 5 were unspecified. In 3 patients, bilateral resections
were performed; one was explicitly described as an open
method, while the remaining two were unspecified.
In 48 patients where follow-up information was available,
most (85%) patients remained alive without disease at follow-
up. Follow-up times ranged from 2 weeks to 14 years, with a
median value of 18 months. The median (range) time of death
for the 7 of 9 patients where information was available was 8
with a range of (3–168) months.
Of 62 studies, the median (range) score was 100% (range
0–100%); 41 scored 100% in the JBI classification (Table 4).
There was a study that scored zero, which was a larger series
of adrenal lesions that included 3 patients with composite
tumours, but provided no relevant information [16].
Discussion
Composite phaeochromocytoma tumours are extremely rare
[9]. Two patients were identified in this unit over a 19-year
period, in addition to the 94 patients identified in this review.
Genetic syndromes including neurofibromatosis 1, MEN
2A, von Hippel Lindau syndrome and watery-diarrhoea
hypokalaemia-achlorhydria (WDHA) syndrome were only
identified in 28% of patients, similar to patients with
phaeochromocytoma alone—a review of 314 patients with
phaeochromocytoma 27.4% with an underlying genetic cause
[74].
The pathogenesis of composite tumours is unclear. Apart
from coincidental occurrence, alteration in the microenviron-
ment of one tumour may favour the formation of a second
tumour arising in the same area [75].
Although not currently included in treatment guidelines
[7], recent small studies have shown 68Ga-dotatate PET scans
to be more specific than MIBG in the diagnosis of
phaeochromocytoma and paraganglioma (PPGL) tumours
[5, 6]. However, this imagingmodality is not widely available.
Of 94 case reports, only seven reported use of alpha blocker
therapy before surgery. Alpha blocker therapy pre-surgery is
currently recommended in all patients with functional
phaeochromocytoma-paragangliomas (PGGLs) to reduce the
risk of hypertensive crisis [7]. However recent studies have
shown that alpha blockade may not have any effect on intra-
operative blood pressure or mortality [76–79].
This review is fairly comprehensive, but it is not possible to
make clear recommendations on management based on a re-
view of case studies. Another limitation of our review is the
discrepancy in reporting quality amongst the case reports.
Conclusion
This review provides comprehensive demographic and clini-
cal information on composite phaeochromocytomas pub-
lished in the literature. These tumours affect men and women
equally, with the majority of diagnoses occurring between the
third and fifth decades. Clinical presentation can be classified
into two main categories: cardiovascular and gastrointestinal.
No genec 
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Fig. 5 Pie chart showing patients with composite phaeochromocytoma in











Fig. 6 Pie chart showing patients with composite phaeochromocytoma
included in the review, stratified by composite tumour components
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Adrenalectomy is the gold standard treatment and prognosis is
good; however, these tumours remain extremely rare and their
occurrence should prompt consideration for genetic testing.
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